CAC 40
7 319,06 -27,09 (-0,37 %) Euro Stoxx 50
4 410,97 -7,54 (-0,17 %) Dow Jones
36 245,50 +294,60 (+0,82 %) EUR/USD
1,0827 -0,0058 (-0,53 %) Gold future
2 073,00 -16,70 (-0,80 %) Bitcoin EUR
38 383,27 +1 766,22 (+4,82 %)
MRK Jan 2024 90.000 call
| Clôture précédente | 12,48 |
| Ouverture | 12,42 |
| Offre | 0,00 |
| Vente | 0,00 |
| Prix d’exercice | 90,00 |
| Date d’expiration | 2024-01-19 |
| Var. jour | 12,42 - 12,48 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 1,11k |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
